Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junya Nakamura

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Platelets|April 10, 2015
Measurement of soluble C-type lectin-like receptor 2 in human plasmaFuminori Kazama, Junya Nakamura, Makoto Osada, et al.
International Journal of Oncology|February 23, 2008
Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumorsNaoya Tatsumi, Yusuke Oji, Naoko Tsuji, et al.
International Journal of Hematology|June 6, 2019
Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: comparison with soluble GPVIOsamu Inoue, Makoto Osada, Junya Nakamura, et al.
International Journal of Oncology|April 11, 2009
Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycleJunya Nakamura, Sayaka Aoyagi, Isamu Nanchi, et al.
International Journal of Cancer|April 23, 2009
WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factorYusuke Oji, Yayoi Kitamura, Eriko Kamino, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, et al.
Therapeutic Advances in Medical Oncology|December 26, 2022
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysisHisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, et al.
Therapeutic Advances in Medical Oncology|March 15, 2021
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Platelets|April 10, 2015
Measurement of soluble C-type lectin-like receptor 2 in human plasmaFuminori Kazama, Junya Nakamura, Makoto Osada, et al.
International Journal of Oncology|February 23, 2008
Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumorsNaoya Tatsumi, Yusuke Oji, Naoko Tsuji, et al.
International Journal of Hematology|June 6, 2019
Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: comparison with soluble GPVIOsamu Inoue, Makoto Osada, Junya Nakamura, et al.
International Journal of Oncology|April 11, 2009
Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycleJunya Nakamura, Sayaka Aoyagi, Isamu Nanchi, et al.
International Journal of Cancer|April 23, 2009
WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factorYusuke Oji, Yayoi Kitamura, Eriko Kamino, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, et al.
Therapeutic Advances in Medical Oncology|December 26, 2022
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysisHisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, et al.
Therapeutic Advances in Medical Oncology|March 15, 2021
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, et al.
Pageof 3